Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia

Medical Science Monitor

Volumn 15, Issue 2, 2009, Pages

  Galińska, Beata ^a   Szulc, Agata ^a   Tarasów, Eugeniusz ^a   Kubas, Bozena ^a   Dzienis, Wojciech ^a   Czernikiewicz, Andrzej ^a   Walecki, Jerzy ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Duration of prodromal symptoms; Duration of untreated psychosis; First episode schizophrenia; Proton magnetic resonance spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; CHLORPROMAZINE; CHOLINE; CREATININE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; INOSITOL; N ACETYLASPARTIC ACID; OLANZAPINE; PERAZINE; PERPHENAZINE; RISPERIDONE;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FRONTAL LOBE; HUMAN; MALE; NEUROIMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOMETRY; PSYCHOSIS; SCHIZOPHRENIA; TEMPORAL LOBE; THALAMUS; TREATMENT OUTCOME; CASE CONTROL STUDY; DEMOGRAPHY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; TIME;

ADULT; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TIME FACTORS;

EID: 63449138812     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. McGlashan TH: Duration of untreated psychosis in first episode schizophrenia: marker or determinant of course? Biol Psychiatry, 1999; 46: 899-907
2. Norman RMG, Lewis SW, Marshall M: Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry, 2005; 187(Suppl.48): 19-23
3. Carbone S, Harrigan S, McGorry PD et al: Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatr Scand, 1999; 100: 96-104
4. Drake RJ, Haley CJ, Akhtar S, Lewis SW: Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry, 2000; 177: 511-15
5. Bottlender R, Sato T, Jager M et al: The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res, 2003; 62: 37-44
6. Marshall M, Lewis S, Lockwood A et al: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. Arch Gen Psychiatry, 2005; 62: 975-83
7. Amminger GP, Edwards J, Brewer WJ et al: Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res, 2002; 54: 223-30
8. Barnes TRE, Hutton SB, Chapman MJ et al: West London first-episode study of schizophrenia. Br J Psychiatry, 2000; 177: 207-11
9. Hoff AL, Sakuma M, Razi K et al: Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia. Am J Psychiatry, 2000; 157: 1824-28
10. Ho B-C, Alicata D, Ward J et al: Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry, 2003; 160: 142-48
11. Heydebrand G, Weiser M, Rabinowitz J et al: Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res, 2004; 68: 1-9
12. Rund BR, Melle I, Friis S et al: Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry, 2004; 161: 466-72
13. Hutton SB, Huddy V, Barnes TRE et al: The relationship between antisaccades, smooth pursuit, and executive dysfunction in first-episode schizophrenia. Biol Psychiatry, 2004; 56: 553-59
14. Madsen AL, Karle A, Rubin P et al: Progressive atrophy of the frontal lobes in first-episode schizophrenia: interaction with clinical course and neuroleptic treatment. Acta Psychiatr Scand, 1999; 100: 367-74
15. Fannon D, Chitnis X, Doku V et al: Features of structural brain abnormality detected in first-episode psychosis. Am J Psychiatry, 2000; 157: 1829-34
16. Ho B-C, Alicata D, Mola C, Andreasen NC: Hippocampus volume and treatment delays in first-episode schizophrenia. Am J Psychiatry, 2005; 162: 1527-29
17. Keshavan MS, Haas GL, Kahn CE et al: Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? J Psychiatr Res, 1998; 32(3-4): 161-67
18. Lappin JM, Morgan K, Morgan C et al: Gray matter abnormalities associated with duration of untreated psychosis. Schizophr Res, 2006; 83: 145-53
19. 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology, 2005: 30: 1949-62
20. Molina V, Sanchez J, Reig S et al: N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr Res, 2005; 73: 209-19
21. Keshavan MS, StanleyJA, Pettegrew JW: Magnetic Resonance Spectroscopy in Schizophrenia: Methodological Issues and Findings-Part II. Biol Psychiatry, 2000; 48: 369-80
22. Bartha R, Williamson PC, Drost DJ et al: Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry, 1997; 54: 959-65
23. Théberge J, Bartha R, Drost DJ et al: Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry, 2002; 159: 1944-46
24. Stanley JA, Williamson PC, Drost DJ et al: An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull, 1996; 22: 597-609
25. Bartha R, Al-Semaan YM, Williamson PC et al: A short proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first- onset schizophrenic patients. Biol Psychiatry, 1999; 45: 1403-11
26. Théberge J, Al-Semaan Y, Williamson PC et al: Glutamate and gluta- mine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry, 2003; 160: 2231-33
27. Ohrmann P, Siegmund A, Suslow T et al: Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res, 2005; 73: 153-57
28. 1H magnetic resonance spectroscopy study at 4.0 Tesla. Psychiatry Research: Neuroimaging, 2004; 131: 107-14
29. Bazire S: Psychotropic Drug Directory 2003/2004. The professionals' pocket handbook and aide memoire. UK: Fivepin Publishing, 2003; 179-81
30. Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry, 2003; 64(6): 663-67
31. Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: Past and current conceptualizations. Schizophr Bull, 1996; 22: 353-70
32. Larsen TK, Johannessen JO, Opjordsmoen S: First-episode schizophrenia with long duration of untreated psychosis. Br J Psychiatry, 1998; 172(Suppl.33): 45-52
33. Guy W: ECDEU Assessment Manual for Psychopathology. DHEW Publ ADM-76-338, 1976; 534-37
34. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull, 1987; 13(2): 261-76
35. Addington D, Addington J, Maticka-Tyndale E: Assessing depression in schizophrenia: The Calgary Depression Scale. Br J Psychiatry, 1993; 163(Suppl.22): 39-44
36. Andreasen NC, Paradiso S, O'Leary DS: "Cognitive dysmetria" as an in- tegrative theory of schizophrenia: a dysfuncion in cortical-subcortical- cerebellar circuitry? Schizophr Bull, 1998; 24: 203-18
37. Stanley JA: Magnetic Resonance Spectroscopy in Schizophrenia: Methodological Issues and Findings-Part I. Biol Psychiatry, 2000; 48: 357-68
38. Murdoch JB, Lampman DA: "Beyond WET and DRY: Optimized Pulses for Water Suppression", Society of Magnetic Resonance in Medicine, Twelfth Annual Meeting, New York, New York, 1993; 1191
39. Wood SJ, Berger G, Velakoulis D et al: Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull, 2003; 29(4): 831-43
40. Cecil KM, Lenkinski RE, Gur RE, Gur RC: Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology, 1999; 20: 131-40
41. Fannon D, Simmons A, Tennakoon L et al: Selective deficit of hippo- campal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol Psychiatry, 2003; 54; 587-98
42. Urenjak J, Williams SR, Gadian DG, Noble M: Specific expression of N- acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem, 1992; 59: 55-61
43. Jung RE, Haier RJ, Yeo RA et al: Sex differences in N-acetylaspartate correlates of general intelligence: An 1H-MRS study of normal human brain. NeuroImage, 2005; 26: 965-72
44. Bustillo JR, Lauriello J, Rowland LM et al: Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res, 2002; 58: 313-21
45. 1H MRS) study. Med Sci Monit, 2007; 13(Suppl.1): 17-22
46. Bertolino A, Callicott JH, Mattay VS et al: The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry, 2001; 49: 39-46
47. 1H MRS) study. Pharmacopsychiatry, 2005; 38: 214-19
48. Bustillo J, Barrow R, Paz R et al: Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology, 2006; 31: 751-56
49. Lindquist DM, Hawk RM, Karson CR, Komoroski RA: Effects of Antipsychotic Drugs on Metabolite Ratios i Rat Brain in Vivo. Magn Reson Med, 2000; 43: 355-58
50. Bertolino A, Callicot JH, Nawroz S et al: Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology, 1998; 18: 1-9
51. Lim KO, Adalsteinsson E, Spielman D et al: Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry, 1998; 55: 346-52
52. 1H-MRS and tissue segmentation. Schizophr Res, 2001; 52: 87-99
53. DeLisi LE: Defining the course of brain structural change and plasticity in schizophrenia. Psychiatry Res: Neuroimaging, 1999; 92: 1-9
54. Keshavan MS, Berger G, Zipursky RB et al: Neurobiology of early psychosis. Br J Psychiatry, 2005: 187(Suppl.48): 8-18